On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press release with information that the Company intends to propose that an extraordinary general meeting resolves that the Company shall enter into voluntary liquidation. The press release also stated that the board intends to apply for a delisting of the Company's shares from Nasdaq First North Growth Market, provided that the general meeting resolves in accordance with the proposal. The rules of First North Growth Market state that a listed company can be given observation status if the issuer has disclosed its intention to enter into liquidation or delist its shares from Nasdaq First North Growth Market. With reference to the above, Nasdaq Stockholm AB decides that the shares in Asarina Pharma AB (publ) (ASAP, ISIN code SE0011641794, order book ID 160270) shall be given observation status. For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50. Nasdaq Stockholm AB
© 2024 GlobeNewswire
